Phase I
toxicities, DLTs, non-small-cell lung cancer
Phase I will include a maximum of 18 patients (only non-small-cell lung cancer patients will be included in this step).
6 +/- 3 patients for the sequential scheme evaluation.6 +/- 3 patients for the concomitant scheme evaluation.As the safety of the anti-TIGIT and anti-PD-L1 combination has been previously validated, we focused the DLTs on radiation-induced toxicities. We chose to accept no more than 22% of radiation-induced toxicities, as patients will undergo additional chemotherapy-related toxicities.